Metabolomics in degenerative brain diseases

Area of Science:

• Neuroscience
• Biochemistry
• Biomarker Discovery

Background:

• Parkinson's, Alzheimer's, and Huntington's diseases are major central nervous system disorders lacking effective biomarkers, accurate diagnosis, and precise treatments.
• Biomarkers are crucial for early diagnosis and disease progression monitoring in neurological conditions.
• Metabolomics offers insights into metabolic alterations linked to genetic and environmental factors in health and disease.

Purpose of the Study:

• To review metabolite alterations associated with Parkinson's, Alzheimer's, and Huntington's diseases.
• To identify potential biomarkers for these neurodegenerative diseases using metabolomic approaches.
• To explore new therapeutic targets based on identified metabolic changes.

Main Methods:

• Review of studies utilizing mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy for metabolomic profiling.
• Analysis of reported metabolite alterations in patients with Parkinson's, Alzheimer's, and Huntington's diseases.
• Comparison of the strengths and limitations of MS and NMR techniques in neurodegenerative disease research.

Main Results:

• Summary of various metabolite changes identified in the three studied central nervous system diseases.
• Highlighting specific metabolite alterations that show potential as diagnostic biomarkers.
• Discussion of how these metabolic changes could inform therapeutic strategies.

Conclusions:

• Metabolomic analysis using MS and NMR provides valuable data on neurodegenerative disease pathology.
• Identified metabolite alterations may serve as promising biomarkers for early diagnosis and disease management.
• Further research into these metabolic pathways could lead to novel treatment targets for Parkinson's, Alzheimer's, and Huntington's diseases.